Insights: DrugPatentWatch - Find Your Next Blockbuster
Business Intelligence on Biologic and Small Molecule Drugs from DrugPatentWatch.com
- Website
- drugpatentwatch.com · all feeds from this site
- Feed URL
https://www.drugpatentwatch.com/blog/feed/amazon-pollycast/
Read it in your FeedListing reader
Or add to: Feedly Inoreader Raw feed
Latest posts
-
Drug Naming Now Costs $28,000 a Word: Inside the USAN, INN, and FDA System That Decides What Every Medicine Is Called
Drug naming is getting expensive for a reason that rarely gets discussed: the “decision system” around nonproprietary names isn’t a simple marketing formality. It’s a compliance workflow with multiple checkpoints, and those checkpoints take time. When Drug Patent Watch wrote…
-
Before You Call: What a Pharma Strategy Team Must Verify Before Approaching a Drug’s Owner
The biggest risk in “partnering” with pharma isn’t who’s the best fit. It’s that you approach the wrong decision-maker for the wrong underlying IP problem. Drug patent watch’s point is simple: before a strategy team ever reaches out to a drug’s owner, they have to verify what…
-
500 Drugs, 5 Years: What to Do With a Patent Expiry List
Most “patent expiry planning” is backwards. Companies spend months building lists of expiring patents. The real decision point is the 6–24 month window after expiry approaches: whether you can win on the one metric the market rewards first, time-to-substitution.…
-
Patent Expiration Isn’t Generic Entry: How to Find the Date That Counts
The “generic entry date” people track is often not the date the market actually changes. In most pharma launches, the real trigger is the first day a competitor can legally market the product without running into Orange Book patent listings, exclusivity, or other legal barriers.…
-
Why Your PBM’s Generic Substitution Policy Is Six Months Behind the Actual Patent Timeline
Your PBM’s generic substitution policy can be “technically correct” and still be six months late. That delay is the quiet business risk: the policy often updates on a cadence that lags the real patent timeline, so patients and plan sponsors may get pushed into coverage decisions…
-
Patent Expiration to Partnership Target: What 9 Deals Show
The biggest misconception in pharma partnering is that patent expiry is a “deadline.” In practice, it’s a negotiation timeline. The 9 deals in DrugPatentWatch’s breakdown show the same pattern repeatedly: parties structure the agreement around what happens immediately before…
-
The API Shipment Data Already Told You Who’s Entering the Market — Nobody on Your Team Is Reading It
The API shipment dataset already tells you who will enter the market next. Most teams miss it because they’re looking in the wrong place. Drug Patent Watch’s point is simple: if you track API shipment patterns closely enough, you can see supply momentum before launch…
-
A Patent Expiry Date Is Not a Pharma Partnership Plan
A patent expiry date is not a pharma partnership plan. It’s a date on a calendar. A plan is the work that has to happen months (sometimes years) before that date, with clear answers to the questions companies get wrong too late. Here’s the uncomfortable part: many partnerships…
-
Drug Patent Portfolios More Than Tripled Since 1990. Here Is What Changed
Everyone talks about “new drug launches.” The bigger shift since 1990 is that patent portfolios didn’t just grow. They multiplied. Drug patent portfolios have more than tripled since 1990, and the change isn’t only about more patents being filed. What changed is how companies…
-
The Territoriality Trap: Why a US Patent Win Means Nothing Where the Molecule Was Never Filed
A “US patent win” can be commercially meaningless if you never filed the molecule where the product is actually sold. That’s the territoriality trap: patent rights don’t travel. You can win in court in one jurisdiction, but still be blocked from enforcement (or even relevance)…
-
Ro vs. Hims & Hers: What the Compounding Crackdown Actually Did
The “compounding crackdown” didn’t just slow down telehealth weight-loss clinics. It changed the business logic for RO, Hims, and Hers by forcing them to rely less on a gray-area supply chain and more on conventional, compliant manufacturing. That matters because most consumers…
-
Authorized Generics vs. Your Forecast: The No-AG Assumption Fails 43% of the Time
Everyone forecasts generics the same way: “90 days before the first eligible launch date.” That assumption breaks when authorized generics enter the picture. Authorized generics (AGs) can let a brand keep selling “generic” supply under a different product label, shifting demand…
-
The State Drug Affordability Board Is Watching Patent Listings You Haven’t Checked in a Year
The most dangerous compliance gap in pharma isn’t missing a submission. It’s assuming “no news” means “no review.” A recent DrugPatentWatch piece explains that the State Drug Affordability Board isn’t just passively tracking what you’ve already disclosed. It’s actively watching…
-
More Patents, Less Signal: Why a Bigger Drug Patent Database Can Give You Worse Intelligence
Everyone assumes “more patents” means better competitive intelligence. The uncomfortable reality: adding a bigger drug-patent database can make your intelligence worse, because it increases noise faster than signal. That’s the hidden failure mode in many patent monitoring…
-
A ‘Strong Patent Portfolio’ Slide Is a Red Flag: What the Evidence Shows
A “strong patent portfolio slide” is sometimes a red flag. Not because patents are bad, but because how companies present them can quietly reveal what they don’t want investors to ask next. In the evidence discussed, DrugPatentWatch highlights a recurring pattern: when the pitch…
-
Delisted Drug Patents: Six Ways a Patent Leaves the Orange Book, and What Each Exit Changes
Most people think “delisting” an Orange Book patent means the patent is dead. It usually means something else: the patent left the Orange Book, and your risk profile quietly changed. Drug Patent Watch lays out six common ways a patent can exit the Orange Book, and each one…
-
Shelved, Not Failed: How AI Finds the Medicines Pharma Abandoned on Purpose
“Abandoned” doesn’t always mean “failed.” In pharma, some drugs get shelved for reasons that have nothing to do with the science, or at least nothing you’d see by looking only at trial outcomes. That matters because a lot of AI work in drug discovery starts from the wrong…
-
Global Patent Expiration Dates: One Drug, Many Clocks
Everyone assumes patent expiry is one clean date. It isn’t. For many drugs, there are multiple “clocks” running at the same time: different patents (composition, formulation, method), different jurisdictions, and different expiry dates that don’t line up. The result is that the…
-
The AB Rating Is the Whole Business Model: Why America’s Branded Generics Live or Die on One Orange Book Letter
Most people think the fight in branded generics is about manufacturing costs. It’s not. The A/B rating is the whole business model, because it decides whether an FDA approval pathway can launch on time or gets stuck behind a single Orange Book letter. If you’re building around…
-
Why a Drug Off-Patent in Europe Can Still Be Protected for Three More Years in the US
A drug “off-patent” in Europe doesn’t mean it’s free to compete everywhere. The big gotcha is that US exclusivity can extend the effective protection window even after European patent expiry. In the US, mechanisms tied to regulatory milestones (not just patents) can delay…